RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

Abstract excerpt

Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL-C, but the molecular target was not previously reported. Using binding assays and X-ray...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors